204 related articles for article (PubMed ID: 21890459)
1. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.
Fioramonti M; Santini D; Iuliani M; Ribelli G; Manca P; Papapietro N; Spiezia F; Vincenzi B; Denaro V; Russo A; Tonini G; Pantano F
Oncotarget; 2017 Mar; 8(12):20113-20121. PubMed ID: 28223547
[TBL] [Abstract][Full Text] [Related]
3. The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies.
Zhang Y; Liang J; Liu P; Wang Q; Liu L; Zhao H
Front Endocrinol (Lausanne); 2022; 13():1063815. PubMed ID: 36589815
[TBL] [Abstract][Full Text] [Related]
4. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma.
Tada Y; Kokabu S; Sugiyama G; Nakatomi C; Aoki K; Fukushima H; Osawa K; Sugamori Y; Ohya K; Okamoto M; Fujikawa T; Itai A; Matsuo K; Watanabe S; Jimi E
Oncotarget; 2014 Dec; 5(23):12317-30. PubMed ID: 25373602
[TBL] [Abstract][Full Text] [Related]
5. Muscadine grape skin extract can antagonize Snail-cathepsin L-mediated invasion, migration and osteoclastogenesis in prostate and breast cancer cells.
Burton LJ; Smith BA; Smith BN; Loyd Q; Nagappan P; McKeithen D; Wilder CL; Platt MO; Hudson T; Odero-Marah VA
Carcinogenesis; 2015 Sep; 36(9):1019-27. PubMed ID: 26069256
[TBL] [Abstract][Full Text] [Related]
6. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
Yin P; Cui S; Liao X; Yao X
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
[TBL] [Abstract][Full Text] [Related]
7. Effects and mechanism of aromatic aminoketone SY0916 on osteoclastic bone destruction.
Wang L; Peng SY; Liu Y; Li P; Wang WJ
Acta Pharmacol Sin; 2010 Apr; 31(4):470-5. PubMed ID: 20208552
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotective Effect of Cimiracemate in Glucocorticoid-Induced Osteoporosis by Osteoprotegerin/Receptor Activator of Nuclear Factor κ B/Receptor Activator of Nuclear Factor Kappa-Β Ligand Signaling.
Ding Z; Shi H; Yang W
Pharmacology; 2019; 103(3-4):163-172. PubMed ID: 30695776
[TBL] [Abstract][Full Text] [Related]
9. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.
Zoi I; Karamouzis MV; Xingi E; Sarantis P; Thomaidou D; Lembessis P; Theocharis S; Papavassiliou AG
Breast Cancer Res; 2019 Dec; 21(1):132. PubMed ID: 31796128
[TBL] [Abstract][Full Text] [Related]
10. The RANK-RANKL-OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer.
De Leon-Oliva D; Barrena-Blázquez S; Jiménez-Álvarez L; Fraile-Martinez O; García-Montero C; López-González L; Torres-Carranza D; García-Puente LM; Carranza ST; Álvarez-Mon MÁ; Álvarez-Mon M; Diaz R; Ortega MA
Medicina (Kaunas); 2023 Sep; 59(10):. PubMed ID: 37893470
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of osteoprotegerin in colorectal cancer cells promotes liver metastasis via activating tumor-associated macrophage.
Hirata W; Itatani Y; Masui H; Kawada K; Mizuno R; Yamamoto T; Okamoto T; Ogawa R; Inamoto S; Maekawa H; Okamura R; Kiyasu Y; Hanada K; Okamoto M; Nishikawa Y; Sugimoto N; Tamura T; Hatano E; Sakai Y; Obama K
Sci Rep; 2023 Dec; 13(1):22217. PubMed ID: 38097649
[TBL] [Abstract][Full Text] [Related]
12. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.
Mercatali L; Ricci M; Scarpi E; Serra P; Fabbri F; Ricci R; Liverani C; Zanoni M; Zoli W; Maltoni R; Gunelli E; Amadori D; Ibrahim T
Int J Mol Sci; 2013 May; 14(6):10683-93. PubMed ID: 23702841
[TBL] [Abstract][Full Text] [Related]
13. RANK/RANKL axis promotes migration, invasion, and metastasis of osteosarcoma via activating NF-κB pathway.
Takeda T; Tsubaki M; Genno S; Tomita K; Nishida S
Exp Cell Res; 2024 Mar; 436(2):113978. PubMed ID: 38382805
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro action mechanism of treatment of glucocorticoid-induced osteoporosis by regulation of osteoprotegerin/receptor activator of nuclear factor-κB pathways by denshensu.
Li J
Cell Mol Biol (Noisy-le-grand); 2023 Oct; 69(10):67-74. PubMed ID: 37953581
[TBL] [Abstract][Full Text] [Related]
15. Iguratimod suppresses sclerostin and receptor activator of NF-κB ligand production via the extracellular signal-regulated kinase/early growth response protein 1/tumor necrosis factor alpha pathway in osteocytes and ameliorates disuse osteoporosis in mice.
Miura T; Etani Y; Noguchi T; Hirao M; Takami K; Goshima A; Kurihara T; Fukuda Y; Ochiai N; Kanamoto T; Nakata K; Okada S; Ebina K
Bone; 2024 Apr; 181():117026. PubMed ID: 38325651
[TBL] [Abstract][Full Text] [Related]
16. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.
Trouvin AP; Goëb V
Clin Interv Aging; 2010 Nov; 5():345-54. PubMed ID: 21228900
[TBL] [Abstract][Full Text] [Related]
17. Bone destruction in chronic otitis media is not mediated by the RANKL pathway or estrogen receptor-alpha.
Heo KW; Noh M; Hur DY; Hong TU; Park SY; Kim WJ
Sci Prog; 2023; 106(3):368504231199204. PubMed ID: 37697808
[TBL] [Abstract][Full Text] [Related]
18. RANKL/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes.
Kondegowda NG; Filipowska J; Do JS; Leon-Rivera N; Li R; Hampton R; Ogyaadu S; Levister C; Penninger JM; Reijonen H; Levy CJ; Vasavada RC
Sci Adv; 2023 Nov; 9(44):eadf5238. PubMed ID: 37910614
[TBL] [Abstract][Full Text] [Related]
19. RANKL signaling drives skeletal muscle into the oxidative profile.
Cavalcanti de Araújo PH; Cezine MER; Vulczak A; Vieira LC; Matsuo FS; Remoto JM; Santos ADR; Miyabara EH; Alberici LC; Osako MK
J Bone Miner Res; 2024 Apr; ():. PubMed ID: 38619281
[TBL] [Abstract][Full Text] [Related]
20. Dual roles of cellular communication network factor 6 (CCN6) in the invasion and metastasis of oral cancer cells to bone via binding to BMP2 and RANKL.
Hochi H; Kubota S; Takigawa M; Nishida T
Carcinogenesis; 2023 Dec; 44(8-9):695-707. PubMed ID: 37590989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
